These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1003 related articles for article (PubMed ID: 27789722)
21. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407 [TBL] [Abstract][Full Text] [Related]
22. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882 [TBL] [Abstract][Full Text] [Related]
23. One-Step Kuo HT; Lepage ML; Lin KS; Pan J; Zhang Z; Liu Z; Pryyma A; Zhang C; Merkens H; Roxin A; Perrin DM; Bénard F J Nucl Med; 2019 Aug; 60(8):1160-1166. PubMed ID: 30737299 [TBL] [Abstract][Full Text] [Related]
24. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548 [TBL] [Abstract][Full Text] [Related]
25. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [ Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643 [TBL] [Abstract][Full Text] [Related]
26. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336 [TBL] [Abstract][Full Text] [Related]
27. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034 [TBL] [Abstract][Full Text] [Related]
28. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178 [TBL] [Abstract][Full Text] [Related]
29. Radiolabeling of PSMA-617 with Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and preclinical evaluation of an Al Huang Y; Li H; Ye S; Tang G; Liang Y; Hu K Eur J Med Chem; 2021 Oct; 221():113502. PubMed ID: 33965863 [TBL] [Abstract][Full Text] [Related]
32. Basaco Bernabeu T; Mansi R; Del Pozzo L; Zanger S; Gaonkar RH; McDougall L; De Rose F; Jaafar-Thiel L; Herz M; Eiber M; Ulaner GA; Weber WA; Fani M J Nucl Med; 2024 Sep; 65(9):1427-1434. PubMed ID: 39025646 [TBL] [Abstract][Full Text] [Related]
33. Alpha-PET for Prostate Cancer: Preclinical investigation using Umbricht CA; Köster U; Bernhardt P; Gracheva N; Johnston K; Schibli R; van der Meulen NP; Müller C Sci Rep; 2019 Nov; 9(1):17800. PubMed ID: 31780798 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen. Lewis MR; Schaedler AW; Ho KV; Golzy M; Mathur A; Pun M; Gallazzi F; Watkinson LD; Carmack TL; Sikligar K; Anderson CJ; Smith CJ Nucl Med Biol; 2024; 136-137():108938. PubMed ID: 39032262 [TBL] [Abstract][Full Text] [Related]
35. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Benešová M; Umbricht CA; Schibli R; Müller C Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475 [TBL] [Abstract][Full Text] [Related]
36. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996 [TBL] [Abstract][Full Text] [Related]
37. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Giesel FL; Hadaschik B; Cardinale J; Radtke J; Vinsensia M; Lehnert W; Kesch C; Tolstov Y; Singer S; Grabe N; Duensing S; Schäfer M; Neels OC; Mier W; Haberkorn U; Kopka K; Kratochwil C Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):678-688. PubMed ID: 27889802 [TBL] [Abstract][Full Text] [Related]
38. Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer. Liolios C; Schäfer M; Haberkorn U; Eder M; Kopka K Bioconjug Chem; 2016 Mar; 27(3):737-51. PubMed ID: 26726823 [TBL] [Abstract][Full Text] [Related]
39. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals. Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903 [TBL] [Abstract][Full Text] [Related]